Assessment of Acute Disease to Reduce Imaging Costs

Overview

Overtesting for Acute Coronary Syndrome(ACS) and Pulmonary Embolism (PE) in low risk Emergency Department(ED) patients can increase exposure of nondiseased patients to radiation, intravenous contrast and anticoagulation. This project addresses question of whether quantitative Pre-Test Probability(PTP) assessed from two validated web-based computer algorithms (the project "webtool"), can improve the diagnostic evaluation of adult patients with charted evidence of chest pain and dyspnea. After a validation phase, the main study will randomize patients to either the Standard care group or the Intervention group, which will receive the output of the ACS and PE webtool that includes the PTP estimates of ACS and PE and one of three recommendations regarding next steps: 1. No further testing, 2. Exclusion with a biomarker protocol, or 3. Immediate imaging +/- empiric anticoagulation.

Full Title of Study: “Quantitative Pretest Probability to Reduce Cardiopulmonary Imaging in the ED”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Screening
    • Masking: None (Open Label)
  • Study Primary Completion Date: May 2012

Interventions

  • Device: Webtool
    • Webtool provides the numeric PTP estimate for ACS and PE, and one of three testing recommendations. For ACS, PTP <2.5% with low clinical suspicion and available follow-up, no further testing; PTP 2.5 to 5.5%: obtain a troponin I measurement at presentation and 120 minutes later, and if both are normal, no further testing; PTP >5.5%: proceed to provocative testing. For PE, PTP<2.5% with low clinical suspicion and available follow-up, no further testing; PTP 2.5-10%, obtain a quantitative D-dimer and if normal, no further testing. PTP 10-20%, proceed directly to pulmonary vascular imaging, and if PTP>20% consider empiric anticoagulation with heparin if no contraindications.

Arms, Groups and Cohorts

  • Experimental: Webtool Output
    • The webtool output group will receive the numeric PTP estimate from webtool output.
  • No Intervention: Standard of Care/No Webtool Output
    • The control group will not receive the numeric PTP estimate.

Clinical Trial Outcome Measures

Primary Measures

  • Efficiency–Mean Cost of Care
    • Time Frame: Day 30
    • Only costs at the enrollment hospital will be used, and only for patients who indicate that they did not visit any other hospital at the time of phone follow-up. Costs would exclude unexpected and unrelated events such as trauma. Additionally, estimated costs associated with the time required of the clinician to gather and enter the 17 variables are included.

Secondary Measures

  • Efficiency–Total Charge of Medical Care
    • Time Frame: Day 30
    • Amount charged for medical care.
  • Safety–Radiation Dose to the Chest
    • Time Frame: Day 90
    • in millisievert (mSv)
  • Effectiveness–Length of Stay in Hospital
    • Time Frame: Day 7
  • Effectiveness–Length of Stay Emergency Department
    • Time Frame: Day 7

Participating in This Clinical Trial

Inclusion Criteria

  • Adult (>17 years) ED patient reports a history of chest discomfort and new or worsened shortness of breath or breathing difficulty, documented in the written history of present illness or review of systems. – Patient must understand English or have a certified translator present. – Physician has ordered or plans to order a 12-lead electrocardiogram. – Patient indicates the site hospital was his or her "hospital of choice" in the event of return visit within 14 days. Randomization Exclusions – Positive urine cocaine test. – Incarceration within 14 days of enrollment. – Patient elopement from medical care (i.e., patients who leave against medical advice).

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 99 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Wake Forest University Health Sciences
  • Collaborator
    • Agency for Healthcare Research and Quality (AHRQ)
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Jeffrey A Kline, MD, Principal Investigator, Indiana University School of Medicine

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.